This study examines ALC-0315 as the ionizable lipid in a non-viral mRNA delivery system for oral-cancer immunotherapy. Its central delivery question is not simply whether a fluorescently labeled nucleic acid enters cells, but whether the formulation supports a sequence of relevant outcomes: mRNA encapsulation and protection, cellular internalization, protein production, antigen presentation, and immune-mediated tumor-cell killing. The paper also evaluates whether combining survivin mRNA-LNPs with a CTLA-4 inhibitor strengthens the resulting immune response. The evidence remains preliminary because the antitumor experiments were performed mainly in vitro or with immune cells isolated from healthy animals rather than in tumor-bearing animals.
The formulation is relevant to ALC-0315 and mRNA-LNP research because it uses an ionizable lipid rather than a permanently cationic lipid as the principal delivery lipid. However, the paper does not include a PEG lipid, a direct PEG-lipid comparison, a biodistribution study, or a direct assay of endosomal escape. The paper's introduction discusses pH-dependent ionization and endosomal disruption as established concepts, but those mechanisms were not directly measured in the experiments reported here.
Research Question
The investigators asked whether an ALC-0315-based LNP could encapsulate an in-vitro-transcribed survivin antigen mRNA and deliver it to immune-relevant cells sufficiently to support survivin protein expression and antigen-specific immune activation. They further asked whether adding an anti-CTLA-4 antibody to survivin mRNA-LNP treatment could reduce regulatory immune activity and increase cytotoxic responses against MOC-1 oral carcinoma cells.
The survivin construct encoded the SVN53-67/M57 antigenic sequence. The plasmid described in the study was used as a DNA template for cloning and in-vitro transcription; it was not delivered to cells as the therapeutic cargo. Accordingly, the reported delivery and translation results should be attributed to survivin mRNA-LNPs, not to plasmid transfection.
Study Design and Methods
mRNA preparation and LNP formulation
The researchers cloned the survivin sequence into a modified pSP64T vector containing an SP6 promoter, untranslated regions, and a poly(A) tail. A PCR product derived from the confirmed plasmid was then used for SP6 in-vitro transcription. The optimized transcription condition reported in the paper used 5 mM nucleotide concentrations, 37 °C, and a 4-hour reaction. The resulting RNA was purified and evaluated by denaturing gel electrophoresis, spectrophotometry, and reverse transcription followed by sequencing. The paper reports 98.7% identity between the resulting sequence and the expected survivin mRNA sequence.
LNPs were produced with a droplet-based microfluidic device. The lipid phase contained ALC-0315, DOPE, and cholesterol at a 50:10:40 molar ratio; the aqueous phase contained citrate buffer at pH 3.5 and 0.05% Tween 80. The selected production conditions were a total flow rate of 90 μL/min and an aqueous-to-organic flow-rate ratio of 3:1. An N/P ratio of 3:1 was used for mRNA loading. The paper identifies Avanti Polar Lipids as the source of ALC-0315 and DOPE and Sigma-Aldrich as the source of cholesterol.
ALC-0315 was initially compared with DOTAP, a cationic lipid, during formulation screening. The authors selected ALC-0315 because they report lower particle size and polydispersity and a greater zeta potential than the DOTAP formulation. This comparison was primarily physicochemical: the study does not provide a complete functional head-to-head comparison of ALC-0315 and DOTAP for mRNA uptake, translation, endosomal release, or immune activity. The listed formulation contains no PEG-lipid, so the study cannot establish how PEGylation would affect particle size, uptake, expression, stability, biodistribution, or tolerability.
Particle and mRNA characterization
Dynamic light scattering gave blank LNPs an average size of 257 ± 114 nm and a polydispersity index of 0.16. The mRNA-loaded formulation had an average size of 306 ± 113 nm, a polydispersity index of 0.11, and a zeta potential of 6.4 ± 5 mV; the abstract reports a comparable loaded-particle size of 305 ± 68 nm. The mRNA encapsulation efficiency was 65 ± 3.9% by a RiboGreen assay. STEM imaging showed spherical particles with smooth surfaces.
The RiboGreen measurement distinguished free RNA from RNA released after Triton X-100 disruption of the LNPs. A dextran sulfate decomplexation experiment showed that the RNA could be released from the lipid complex and migrate similarly to free mRNA. In an RNase H assay, naked mRNA was degraded, whereas the encapsulated mRNA remained 80 ± 2.1% intact after treatment. This supports protection from the specific enzymatic challenge used in the experiment; it does not establish long-term storage stability, serum stability, release kinetics, or in vivo persistence.
Separating uptake from translation
For cellular uptake, the investigators synthesized cyanine-labeled survivin mRNA and measured the percentage of fluorescent-positive bone marrow-derived dendritic cells by flow cytometry after 2, 4, or 6 hours. This assay detects cell-associated labeled RNA signal after washing and therefore serves as an internalization-associated readout. It does not demonstrate that the labeled RNA reached the cytosol, escaped endosomes, remained intact, or was translated.
Functional protein expression was evaluated separately in HFF-1 human forearm fibroblasts treated with survivin mRNA-LNPs for 18 hours. Confocal microscopy used antibodies against survivin and a poly-histidine tag. The paper therefore used antigen and tag immunofluorescence rather than an EGFP or luciferase reporter. The reported protein signal is a translation-related readout, whereas the cyanine experiment is an uptake-related readout; the two should not be treated as interchangeable measurements.
Immune and antitumor assays
Bone marrow-derived dendritic cells were treated with blank LNPs, scrambled mRNA-LNPs, survivin mRNA-LNPs, CTLA-4 inhibitor, or the combination. Some experiments used lipopolysaccharide stimulation to model an inflammatory condition. MHC class I and class II expression was measured by flow cytometry, followed by coculture with mouse splenocytes to evaluate T-cell populations, including CD4-positive, CD8-positive, activated CD8-positive CD25-positive, and regulatory CD4-positive CD25-positive FoxP3-positive cells.
Activated immune cells were then cocultured with fluorescently labeled MOC-1 oral carcinoma cells and healthy cheek cells. Cancer-cell and cheek-cell populations were distinguished with different CellTracker dyes. These dye signals were used to estimate relative cell populations and cytotoxicity; they were not mRNA-delivery signals. Cytokines were measured by ELISA. In a separate healthy-mouse priming experiment, animals received a submandibular injection of blank LNPs or survivin mRNA-LNPs at 30 μg mRNA equivalent per administration, either once or twice one week apart. The methods describe the CTLA-4 inhibitor as a separate treatment in immune and coculture experiments rather than as a second cargo encapsulated in the LNP.
Main Findings
Formulation and protection
The ALC-0315 formulation formed spherical, moderately polydisperse particles of approximately 300 nm with 65 ± 3.9% mRNA encapsulation. The increase in particle size and reduction in zeta potential after mRNA loading were interpreted by the authors as evidence of lipid-mRNA complexation. The decomplexation experiment confirmed that the RNA could be released from the lipid complex under the tested conditions. The RNase assay further showed that encapsulation substantially protected the RNA relative to naked mRNA in that assay.
These results establish basic formulation functionality, but they do not show that the particles released intact mRNA into the cytosol. In particular, the study did not directly image endosomal escape, quantify cytosolic mRNA, or measure translation in the same dendritic-cell population used for the uptake experiment.
Uptake and protein output were related but distinct outcomes
In bone marrow-derived dendritic cells, naked labeled mRNA produced approximately 18% fluorescent-positive cells at 6 hours at the 15 μg dose and approximately 24% at the 30 μg dose. The corresponding mRNA-LNP values were approximately 48% and 60%. Thus, the LNP increased the measured cell-associated cyanine signal relative to naked mRNA under the reported conditions.
Endocytosis-inhibitor experiments reduced the fluorescent-positive population from 57 ± 5% in the untreated uptake condition to 23 ± 2.2% with the caveolin inhibitor and to 12 ± 1.5% and 12 ± 2.6% with clathrin-mediated endocytosis and macropinocytosis inhibitors, respectively. The authors therefore interpret uptake as involving multiple endocytic routes, with substantial contributions from clathrin-mediated endocytosis and macropinocytosis. Because chemical inhibitors can affect cell physiology and trafficking beyond a single pathway, these findings suggest pathway involvement rather than proving a unique uptake mechanism or demonstrating endosomal escape.
Separate HFF-1 experiments provided evidence of translated survivin and poly-histidine-tagged protein after mRNA-LNP treatment. Survivin and poly-histidine signal colocalization was 59 ± 9.3% in treated cells compared with 32 ± 4.3% in controls. This experiment supports functional protein production from the delivered mRNA in HFF-1 cells. It does not quantify translation in BMDCs, establish the fraction of internalized RNA that was translated, or demonstrate that uptake and protein expression were directly correlated in individual cells.
Antigen presentation and immune activation
Survivin mRNA-LNPs increased MHC class I expression in dendritic-cell assays. Under unstimulated conditions, MHC class I values were reported as 43.3 ± 1.96 for survivin mRNA-LNPs and 50.7 ± 4.61 for the combination with CTLA-4 inhibition, compared with 22.3 ± 1.9 in the control group. With LPS stimulation, the corresponding values were 66.1 ± 1.1 and 70.4 ± 1.8. MHC class II changes were more modest. These measurements support enhanced antigen-presenting-cell activation under the tested conditions, but they do not independently prove that the antigen was generated exclusively through cytosolic translation rather than through other processing or innate-stimulation effects.
Survivin mRNA-LNPs increased CD8-positive T-cell and activated CD8-positive CD25-positive T-cell responses, particularly under LPS stimulation. The standalone survivin mRNA-LNP condition also increased regulatory T-cell levels in the reported coculture system, whereas the combination with CTLA-4 inhibition reduced regulatory T-cell levels relative to survivin mRNA-LNPs alone. The combination did not consistently increase every T-cell subset beyond the mRNA-LNP condition, so the results support immune modulation but do not establish a universal synergistic effect.
In cocultures, survivin mRNA-LNPs reduced MOC-1 cancer-cell viability more than control, blank-LNP, and scrambled-mRNA conditions. Under LPS-stimulated conditions at a 1:5 splenocyte-to-cancer-cell ratio, the paper reports relative reductions in malignant-cell viability of 38.4% for survivin mRNA-LNPs and 53.2% for the combination. Healthy cheek-cell death remained below 3 ± 0.9% in that condition. In unstimulated assays, the survivin mRNA-LNP and combination groups also produced greater cancer-cell cytotoxicity than the control formulations. Because these results come from immune-cell cocultures rather than direct treatment of an established tumor, they demonstrate ex vivo cytotoxic potential rather than therapeutic tumor control.
The cytokine results were formulation- and combination-dependent. Survivin mRNA-LNPs increased IFN-γ and IL-12 relative to controls, CTLA-4 inhibition produced a strong TNF-α response under LPS stimulation, and the combination produced the highest reported IL-2 concentration. These extracellular cytokine measurements are supporting evidence for immune activation; they do not serve as direct measures of mRNA delivery or translation.
Healthy-animal priming and tolerability-related observations
Submandibular administration of survivin mRNA-LNPs to healthy C57BL/6 mice increased several CD4-positive, CD8-positive, and activated CD8-positive populations in spleen, lymph nodes, thymus, and blood. A second dose strengthened some responses, although not every population increased further after boosting. Treg frequencies also increased in several compartments, including the spleen after the double-dose regimen. This finding is important because immune activation and regulatory-cell expansion occurred together.
Body weight remained stable in the single-dose study and increased across groups in the double-dose study. The authors reported transient temperature increases, reaching 99.5 ± 1.0 °F in the single-dose mRNA-LNP group and 100.2 ± 0.8 °F after the second dose, followed by stabilization. Food intake decreased shortly after dosing and recovered. No substantial weight loss or adverse effects were observed in the reported monitoring period. Spleen and lymph-node enlargement were observed after survivin mRNA-LNP treatment, particularly after two doses; these findings were interpreted in the context of immune activation, but they also show why organ-level safety assessment remains necessary.
The healthy-mouse experiment should not be described as biodistribution or organ targeting. The injection was placed in the submandibular region to engage local lymph nodes, and immune tissues were later harvested for cell analysis, but the study did not track labeled LNPs or quantify particle or mRNA accumulation in those organs.
Limitations
- Limited formulation comparison: ALC-0315 was screened against DOTAP for selected physicochemical properties, but the paper does not provide a full functional comparison of the two lipids. No PEG-lipid formulation or PEG-density comparison was reported.
- No direct endosomal-escape measurement: Uptake-inhibitor experiments identify possible internalization pathways, but they do not measure endosomal release, cytosolic delivery, or ribosome access.
- Uptake is not expression: Cyanine-positive flow-cytometry events indicate labeled-mRNA-associated cellular signal after washing. They do not establish intact mRNA delivery or translation. Translation was assessed separately in HFF-1 cells using survivin and poly-histidine immunofluorescence.
- Different cell systems: Uptake was measured in BMDCs, whereas translation was assessed in HFF-1 fibroblasts. The study therefore does not directly quantify the uptake-to-expression relationship in the antigen-presenting cells central to the immune assays.
- No tumor-bearing efficacy study: The antitumor evidence came from MOC-1 cocultures and splenocytes isolated from healthy, LNP-primed mice. The authors state that orthotopic or syngeneic tumor-bearing models are needed.
- No biodistribution or pharmacokinetics: The study did not quantify LNP or mRNA distribution, organ exposure, circulation time, or clearance. Immune changes in spleen, thymus, lymph nodes, and blood should not be treated as direct evidence of organ targeting.
- Incomplete stability and safety characterization: RNase protection was demonstrated, but long-term storage stability, release kinetics, systemic pharmacokinetics, and comprehensive organ toxicity were not evaluated. The authors also identify the need to assess fibroblasts, endothelial cells, and systemic organs more broadly.
- Interpretive limits of the combination data: The combination of survivin mRNA-LNPs and CTLA-4 inhibition often improved immune or cytotoxicity readouts, but the study did not establish formal pharmacologic synergy and did not show that CTLA-4 inhibitor was co-encapsulated with the mRNA.
Overall, the study provides a connected but incomplete delivery-to-function dataset: ALC-0315 LNPs encapsulated and protected survivin mRNA, increased labeled-RNA uptake, supported detectable antigen-protein output in a separate cell model, and generated immune activity in vitro and after healthy-animal priming. The evidence supports further investigation of this formulation platform, while leaving PEG-lipid effects, endosomal escape, biodistribution, storage stability, and therapeutic efficacy in tumor-bearing models unresolved.
Source
The paper reports that the authors have a patent application and/or registration related to the work. The study was financially supported by the Anusandhan National Research Foundation under core research grant CRG/2021/005484.